Call for Abstracts
Abstract Submission Period
July 24 (Thu) - September 1 (Mon), 2025, 17:00
July 24 (Thu) - September 8 (Mon), 2025, 17:00
July 24 (Thu) - Call for Abstracts has been closed.
We recommend submitting your application with sufficient time to spare, as heavy traffic is expected just before the deadline, which may cause network congestion and interfere with presentation registration.
While it is possible to modify the registered abstract content online until the deadline, please note that modifications may not be possible due to congestion just before the deadline.
The email address you register will be used for communications regarding the 56th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery.
Please note that changes to co-authors and other details cannot be accepted after the registration deadline, so please be sure to complete any modifications during the presentation registration period.
While it is possible to modify the registered abstract content online until the deadline, please note that modifications may not be possible due to congestion just before the deadline.
The email address you register will be used for communications regarding the 56th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery.
Please note that changes to co-authors and other details cannot be accepted after the registration deadline, so please be sure to complete any modifications during the presentation registration period.
Eligibility Requirements
- Presentations are limited to unpublished original topics only.
- For inquiries regarding membership, please contact the Japanese Association for Thoracic Surgery office.
Membership Inquiry Contact
Japanese Association for Thoracic Surgery (NPO) Room 202, 2nd Floor, Hirahara Building, 3-9-11 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
TEL：+81-3-5842-2301 FAX： +81-3-5842-2302
Email：jimu@jscvs.org
URL：https://jscvs.or.jp/
Presentation Format (Presentation Categories)
Main Theme Session
The author who selected “Main Theme Session” can choose whether to apply for “General Session (Oral/Poster/Video)” if not accepted as Main Theme Session.
■Valve
| Session Theme | |
|---|---|
| 1 |
AVR with annular enlargement~ how I do it
Several techniques for annular enlargement in AVR, such as the Konno, Manougian, Nicks, and more recently the Y-incision method, have been reported. Understanding each technique’s advantages and disadvantages is essential for appropriate selection. While Japanese patients have a lower risk of patient–prosthesis mismatch (PPM), a lifetime management approach—including implanting a larger valve and enlarging the sinus of Valsalva and sinotubular junction—is crucial to prevent future PPM and coronary obstruction during TAVI. Indications and strategies differ between young, low-risk patients and elderly, high-risk patients, raising the question of how aggressively to pursue annular enlargement. This session will discuss optimal approaches tailored to Japanese patients and future treatment strategies.
|
| 2 |
Controversies in the surgical management of aortic root abscess ~commando, conduit choice, annular manipulation~
Aortic root abscess carries a poor prognosis without proper surgical treatment. Extensive infection often requires radical debridement and the Commando procedure. While homografts offer infection resistance, durability and availability are concerns, and conduit choice remains controversial. Indications for patch repair and annular reconstruction materials are also key issues. This session will share expert experiences and discuss indications, technical tips, conduit options, and annular reconstruction strategies to guide future surgical management.
|
| 3 |
Surgical management of atrial functional MR in the TEER era
Surgical treatment for atrial functional mitral regurgitation (AFMR) includes a variety of procedures such as mitral valve repair, valve replacement, left atrial plication, and the Maze procedure, targeting both the mitral valve complex and the left atrium. These are often combined to provide comprehensive therapy. However, the criteria for indication are not standardized, and treatment strategies vary greatly depending on the institution and surgeon. Meanwhile, the MitraClip (TEER) procedure, which was previously limited to high-risk open-heart surgery cases, has made remarkable progress in recent years. With expanded indications and consistent short-term outcomes, TEER has increased its presence as a treatment option for AFMR. In this session, we will systematically review the indication criteria and outcomes for each surgical procedure, and discuss the role and direction of surgery for AFMR in the era of TEER.
|
| 4 |
Failure mode of degenerative MR repair ~artificial chordae, ring, or others?~
While valve repair for degenerative mitral regurgitation (MR) is an established procedure, it remains difficult to completely prevent recurrence. In this session, we aim to explore how to reduce recurrence rates by discussing the causes of recurrent MR based on echocardiographic findings at early and late phases as well as intraoperative findings during reoperations. What are the risk factors and mechanisms of recurrence in the early and late phases? Why and how do artificial chordae rupture or elongate? Do ring selection and suture techniques contribute to recurrent MR? What are the possibilities and approaches for re-repair? We particularly look forward to presentations from institutions with extensive experience in follow-up echocardiographic data and reoperative cases.
|
| 5 |
MICS/Robot for complex valvular lesion
Minimally invasive cardiac surgery (MICS) and robot-assisted procedures have emerged as promising approaches for treating complex valvular diseases. Even in cases where conventional open-heart surgery poses significant challenges, the enhanced precision and magnified visualization offered by these techniques are expected to improve both safety and reliability. However, limitations such as restricted tactile feedback, narrow operative fields, the inability to directly touch the heart, and the tendency toward solo surgery must also be acknowledged. This session will explore the potential of MICS and robotic surgery in managing challenging cases such as complex valvular lesions and reoperations. We will discuss technical innovations, surgical outcomes, and future perspectives, aiming to share cutting-edge insights into how these new minimally invasive technologies may overcome the current limitations of complex valve repair.
|
| 6 |
Isolated TR surgery -Can cardiac surgeons play any role ?
raditionally, tricuspid regurgitation (TR) has been considered a secondary lesion associated with left-sided valvular disease, and surgical indications for isolated TR have been limited. However, the 2020 valvular heart disease treatment guidelines included surgical indications for isolated TR in elderly patients with a history of open-heart surgery or atrial fibrillation, sparking active discussions about the optimal timing for intervention before it becomes “too late.” On the other hand, surgical treatment for isolated TR still carries a high perioperative risk. Particularly in high-risk cases with impaired liver and kidney function, selecting an appropriate treatment option remains challenging. In this session, we will systematically review the indications, timing, procedures, and outcomes of surgical treatment for isolated TR. Furthermore, we will consider the evolving role-sharing with transcatheter therapies and discuss the types of cases in which cardiac surgeons can truly demonstrate their value.
|
| 7 |
Tricuspid surgery ~How to determine surgical indication?
The surgical indication for tricuspid valve intervention remains ambiguous, even within current clinical guidelines, often leaving clinicians uncertain in real-world practice. Multiple factors—such as primary versus secondary lesions, isolated tricuspid pathology, concomitant left heart surgery, progression of right heart failure, and associated organ dysfunction like liver cirrhosis—intertwine to complicate decision-making regarding optimal timing and surgical strategy. This session aims to establish clearer guidance on tricuspid valve surgery by discussing the latest evidence and clinical insights. Through this dialogue, we hope to take a significant step toward standardizing indications and improving patient outcomes.
|
| 8 |
LAA management ~when and how~
With the advent of left atrial appendage (LAA) closure devices, it has become possible to close the LAA on a beating heart without the use of cardiopulmonary bypass. The therapeutic goals for atrial fibrillation (AF) are to restore sinus rhythm through rhythm control and to prevent thrombus formation within the LAA. However, several large-scale clinical trials, including the AFFIRM study, have shown a tendency for rate control to yield outcomes comparable to or even better than rhythm control. As a result, the concept of "LAA management"—performing LAA closure without rhythm control—is becoming increasingly widespread, based on the belief that stroke prevention is sufficient even if AF persists. In this session, we would like to discuss the optimal timing and method for implementing LAA management.
|
| 9 |
MICS vs. Full Sternotomy Biatrial Maze: Are the Outcomes Truly Equivalent?
Surgical treatment for atrial fibrillation has been centered on the biatrial Maze procedure for over 40 years. The biatrial Maze procedure not only enables rhythm control by restoring sinus rhythm but also prevents thrombus formation in the left atrial appendage by closing it. While favorable outcomes of the biatrial Maze via median sternotomy have been demonstrated, in the current era where minimally invasive cardiac surgery is increasingly demanded, it is necessary to discuss whether the MICS biatrial Maze procedure can achieve outcomes equivalent to those of the sternotomy approach. This should be considered from the perspectives of rhythm control and prevention of intra-atrial thrombosis.
|
■Heart Failure
| Session Theme | |
|---|---|
| 1 |
Recent advancements and limitations of short-term MCS in protected cardiac surgery, post-carditomy shock and bridge to durable VAD
Cardiogenic shock remains an unavoidable and critical challenge in the surgical management of severe cardiac cases, and the importance of mechanical circulatory support (MCS) in this context is drawing increasing attention. In the recently revised ACC/AHA guidelines for acute coronary syndrome (ACS)—the first update in 12 years—driven in part by the DanGer AMI-Shock trial, the use of Impella in AMI-induced shock has been upgraded to a Class IIa recommendation. In contrast, ECLS (PCPS) and IABP, which failed to demonstrate survival benefit in trials like ECLS-Shock, have been downgraded to Class III. Additionally, the 2024 AATS Expert Consensus recommends preoperative Impella use in AMI-Shock undergoing CABG as Class I, and its use in mechanical complications such as papillary muscle rupture, ventricular septal defect, and cardiac rupture as Class IIa–IIb. Nevertheless, MCS still poses unresolved challenges, including limb ischemia, bleeding, and hemolysis. In this session, we hope to present and discuss institutional approaches to MCS by cardiac surgeons, supported by clinical cases and data analyses, to further advance best practices.
|
| 2 |
Cutting edge technologies of heart replacement therapy ~xenograft, TAH, beating heart transplantation (No application, all speakers assigned)
Surgical treatment for end-stage heart failure is rapidly evolving beyond heart transplantation and ventricular assist devices (VAD). In recent years, significant progress has been made toward the clinical application of novel therapies such as xenotransplantation and total artificial hearts (TAH). In this session, we welcome leading pioneers in the field who are shaping the future of surgical heart failure treatment. Among them are Dr. Mohammad M. Mohiuddin from the University of Maryland, who performed the world’s first clinical xenotransplantation using a genetically modified pig heart, and Dr. Paul Jansz from St. Vincent’s Hospital in Australia, who achieved the world’s first hospital discharge of a patient supported by the BiVACOR total artificial heart. They will share cutting-edge insights and discuss the future directions of this rapidly advancing field. This session promises to be a valuable opportunity to explore the next frontier in heart failure therapy.
|
| 3 |
How to manage AR, MR, post-TEER MV during durable LVAD implantation
"With the advent of the Destination Therapy (DT) era, the use of implantable left ventricular assist devices (LVAD) has expanded, leading to increasing diversity in patient backgrounds. In particular, advancements in catheter-based heart failure therapies have resulted in a growing number of patients receiving LVADs after undergoing treatment with temporary circulatory support devices or transcatheter mitral valve repair. These cases often require more patient-specific decision-making, not only regarding whether to intervene in pre-existing valvular diseases, but also in considering individualized treatment strategies. This evolving field can be seen as involving “new valvular diseases,” where existing guidelines may not apply, and the development of new evidence is highly anticipated. In this session, we aim to discuss institutional approaches to intervention and surgical techniques, ultimately contributing to the creation of Japan-specific evidence to improve both early and long-term outcomes.
|
| 4 |
Destination Therapy; current evolution and future challenges
"This session will focus on Destination Therapy (DT) using implantable ventricular assist devices (VAD), and will discuss the latest insights and future challenges from multiple perspectives, including patient selection, surgical techniques, postoperative management, quality of life (QOL), and home care support. DT is positioned as a definitive treatment for patients with advanced heart failure who are not eligible for heart transplantation, and its importance is expected to grow further. We invite a wide range of presentations on the optimization and future prospects of DT in the treatment of heart failure, based on domestic and international clinical experience and evidence.
|
| 5 |
Impact of prolonged Impella 5.5 support on outcomes
Although the labeled duration of use for Impella 5.5 is 30 days, in real-world clinical practice, it is not uncommon for the device to be used beyond this period. In some cases, longer-term circulatory support is achieved by replacing the device on the same or contralateral side as needed. This session will explore how the possibility of extended support—previously difficult with earlier Impella models—has impacted clinical outcomes and complications, as well as its clinical significance and limitations. Additionally, we will discuss treatment strategies anticipating long-term support, the optimal timing for device transition, and future directions for its use.
|
■Coronary
| Session Theme | |
|---|---|
| 1 |
Surgical challenges of MICS/Robotic CABG
In recent years, interest in MICS CABG (Minimally Invasive Coronary Artery Bypass Grafting) has been growing. However, according to data from the JCVSD, the adoption rate as of 2022 remains low, at only 4%. In particular, for patients with multivessel disease, clinicians often face challenges not only in determining the indication for MICS CABG but also in deciding whether to perform multivessel MICS CABG or to opt for a hybrid approach in combination with PCI. On the technical front, new approaches are gaining attention—such as internal thoracic artery (ITA) harvesting using robotic or endoscopic techniques, and TCRAT (Total Coronary Revascularization via Left Anterior Thoracotomy), which allows for complete revascularization under cardioplegic arrest through a left anterior thoracotomy. These advancements hold promise for further development in the field. In this session, we hope to engage in discussions on the challenges of implementing MICS CABG, as well as technical innovations aimed at expanding its indications.
|
| 2 |
What is the best configuration of RITA graft ~in situ, free, or composite~?
The optimal choice and configuration of the second graft following the use of the left internal thoracic artery (LITA) remain subjects of ongoing debate. In Japan, many centers prefer the right internal thoracic artery (RITA) as the second graft, and various configurations have been proposed, including in situ, free, I-composite, Y-composite, and composite grafts with other conduits. In this session, we look forward to presentations of long-term outcomes from each institution’s experience using RITA as a second graft in CABG procedures. Through these case-based discussions, we aim to explore the advantages and disadvantages of each configuration from multiple perspectives. In particular, we hope to engage in a vigorous exchange of views—grounded in both evidence and clinical experience—regarding which technique is most beneficial in real-world practice and which might become the future standard.
|
| 3 |
Benefits and pitfalls of no touch SVG
This session will examine the advantages and challenges of No-touch saphenous vein grafts (NT-SVG), which were reported in 2015 to have superior long-term patency. As their use as second grafts becomes more widespread in Japan, the discussion will reflect the current clinical context. NT-SVG harvesting preserves perivascular fat tissue, endothelium, and vasa vasorum, while avoiding high-pressure distension, resulting in an 83% patency rate at 16 years postoperatively. Furthermore, large-scale trials have demonstrated not only a reduction in graft occlusion but also suppression of adverse events such as recurrent angina, non-fatal myocardial infarction, and repeat revascularization. However, issues remain, including harvesting site complications, transient cutaneous sensory disturbance, and risk of graft kinking. This session will delve into the mechanisms underlying improved graft patency and strategies for complication prevention, sharing the latest findings and discussing real-world applications and future perspectives.
|
| 4 |
Real-world management of ischemic MR at CABG following controversial RCTs
Following the controversial CTSN randomized controlled trials, the treatment strategy for ischemic mitral regurgitation (MR) has been shifting toward a more conservative approach. For moderate MR, CABG alone is increasingly considered sufficient, while for severe MR, CABG combined with mitral valve replacement (MVR) or transcatheter edge-to-edge repair (TEER) is becoming the preferred direction. One of the key drawbacks of these studies is the question of whether mitral valve repair (MVP) was performed appropriately. Since the underlying cause of ischemic MR lies in the left ventricle, addressing only the valve leaflets is often inadequate. Therefore, it remains to be clarified how subvalvular interventions during MVP can improve outcomes in ischemic MR. Similarly, the role of TEER in this context is still evolving. This session aims to foster a multifaceted discussion on the real-world management of ischemic MR in the setting of CABG, including these various interventional strategies.
|
| 5 |
How to manage Low EF CABG ~OPCAB, CPB, Impella~
Coronary artery bypass grafting (CABG) in patients with reduced left ventricular ejection fraction (EF) remains one of the most challenging procedures in cardiovascular surgery. In such cases, the perioperative risk is significantly elevated, necessitating meticulous strategies from surgical indication and procedural selection to perioperative management. Recent advances in off-pump CABG (OPCAB) techniques have enabled less invasive revascularization without the use of cardiopulmonary bypass (CPB). At the same time, traditional on-pump CABG continues to deliver favorable outcomes with appropriate myocardial protection. Moreover, the introduction of mechanical circulatory support devices such as Impella has made it possible to perform surgical revascularization even in severely compromised patients who were previously considered inoperable. This symposium aims to explore optimal treatment strategies for patients with low EF undergoing CABG. We will examine the indications and limitations of OPCAB, CPB-assisted surgery, and Impella-supported procedures, with the goal of advancing personalized surgical approaches tailored to each patient's condition. By sharing institutional experiences, we hope to contribute to the development of evidence-based treatment guidelines.
|
■Aorta
| Session Theme | |
|---|---|
| 1 |
Malperfusion following acute aortic dissection (Type A & B) ~how to manage?
"Although outcomes in the treatment of acute aortic dissection have improved—with early mortality now below 10% for both type A and type B—further improvement has plateaued. In cases involving cardiac tamponade or rupture severe enough to cause out-of-hospital cardiopulmonary arrest, survival is extremely difficult. Treatment outcomes are influenced by regional emergency transport systems and institutional resources. When malperfusion of the brain, coronary arteries, or abdominal organs occurs, the condition rapidly worsens, and organ-specific management based on the severity of dysfunction is required. However, in emergency settings, it is often difficult to objectively assess the severity of organ dysfunction caused by malperfusion. It also remains challenging to determine whether to proceed first with central repair or with endovascular/interventional strategies aimed at restoring organ perfusion through extracorporeal circulation. This session aims to discuss the evaluation of malperfusion severity in acute aortic dissection, treatment selection algorithms (flowcharts), and treatment outcomes based on these approaches.
|
| 2 |
Contemporary outcomes of TAAA repair ~Open vs Endovascular~
This session will focus on the latest treatment outcomes and strategies for thoracoabdominal aortic aneurysms (TAAA), examining both open surgery and endovascular repair. In recent years, the approval of off-the-shelf multi-branch stent grafts in the United States has rapidly expanded the indications for endovascular treatment in clinical practice. Meanwhile, advances in perioperative management—including spinal cord protection—and surgical techniques have steadily improved outcomes for open repair. In Japan as well, the approval of commercially available stent grafts for TAAA is anticipated, making it increasingly important to determine how best to utilize the full spectrum of treatment options, including physician-modified endografts (PMEG) and open surgery. This session will explore contemporary treatment strategies and outcomes based on both domestic and international experience, with an emphasis on practical clinical application.
|
| 3 |
Tips and pitfalls of Frozen elephant trunk
In Japan, a decade has passed since the commercial Frozen Elephant Trunk (FET) graft became available in 2014. Since then, its use has expanded beyond the treatment of acute aortic dissection to include true aneurysms and chronic aortic dissections. More recently, integrated grafts combining FET with four-branched prosthetic grafts, as well as devices featuring non-stented distal segments, have also become available, further broadening the range of graft options. In this session, we invite discussion on how FET treatment is being utilized at each institution, including the selection and differentiation of currently available FET grafts, along with the advantages and potential pitfalls associated with each type
|
| 4 |
False lumen management for type B dissection ~open repair, endovascular, others~
Traditionally, the treatment strategy for Stanford type B aortic dissection has been medical therapy in cases without complications. However, it has become evident that a certain proportion of these cases eventually progress to thoracoabdominal aneurysms. Against this background, the value of preemptive TEVAR has gained attention in recent years, with the goal of achieving more favorable aortic remodeling through adjunctive techniques such as the PETTICOAT technique, the STABILISE technique, and extended TEVAR. For chronic thoracoabdominal aneurysms, treatment options include open repair, TEVAR, false lumen coil embolization, the Candy Plug technique, and the Knickerbocker technique. This session will comprehensively discuss the current state and future perspectives of type B aortic dissection management, spanning from the acute to the chronic phase.
|
| 5 |
Latest options for arch aneurysm repair
Open surgical repair of aortic arch aneurysms via median sternotomy has made significant advancements since the establishment of cerebral protection techniques and is considered a standard treatment with stable long-term outcomes in Japan. However, thoracic endovascular aortic repair (TEVAR) and hybrid procedures have contributed to improved outcomes in challenging cases, such as elderly patients with frailty, those with severe atherosclerotic disease, patients with comorbid organ dysfunction including impaired pulmonary function, and patients with extensive arch aneurysms difficult to approach through a median sternotomy. This session will present the latest updates aimed at improving outcomes in aortic arch aneurysm repair from multiple perspectives, including a re-evaluation of the over-20-year long-term outcomes of total arch replacement, treatment strategies for frail elderly patients, stroke prevention in cases with severe atherosclerotic burden, perioperative strategies for patients with organ dysfunction, surgical approaches to extensive arch aneurysms, the use of the frozen elephant trunk (FET), and techniques to reduce the need for late reintervention after TEVAR.
|
| 6 |
Surgical challenges of valve sparing aortic root replacement ~TAD, bicuspid valve, elderly ~
Valve-sparing aortic root replacement (VSARR) has become widely established as a standard surgical technique, and with its growing adoption, indications have expanded to include increasingly challenging cases. These include thoracic aortic disease (TAD) involving extensive pathology from the ascending aorta and arch to the descending aorta, bicuspid aortic valve (BAV), and even elderly patients. While VSARR represents an ideal option for younger patients, the increased surgical invasiveness associated with extensive aortic replacement for TAD and the technical complexity of BAV repair present significant challenges. Careful patient selection is essential, with close consideration of surgical risk and long-term durability of the native valve. Given the excellent outcomes of the Bio-Bentall procedure, there remains debate regarding the appropriateness of expanding VSARR indications to older patients. In this session, we aim to discuss how each institution approaches these complex cases, including the strategies and criteria used to determine surgical indications and technique selection.
|
■Vascular
| Session Theme | |
|---|---|
| 1 |
Surgical planning in EVAR for hostile/short neck
In recent years, EVAR has become the standard treatment for abdominal aortic aneurysms (AAA); however, preoperative planning and strategic approaches for cases with hostile necks or short necks remain significant challenges. This session aims to broadly share and discuss practical solutions to issues encountered in clinical practice, including specific preoperative planning techniques for challenging neck anatomies, criteria for case selection, choice of deployment devices, strategies for securing the landing zone, and measures for preventing complications. By sharing insights from each institution—including lessons learned from past experiences and failures, as well as key considerations in preoperative planning when using new devices—we aim to further develop safe and reliable EVAR strategies.
|
| 2 |
Preemptive treatment for type 2 endoleak after EVAR ~when and how ?
As long-term outcomes of EVAR for abdominal aortic aneurysms (AAA) become clearer, Type II endoleaks have drawn increasing attention as a major cause requiring secondary interventions. In open surgical graft replacement, the inferior mesenteric artery (IMA) can be reconstructed, and the lumbar arteries are ligated as the aneurysm sac is opened. However, in EVAR, the management of these branch vessels has not been standardized, nor have they been addressed as specific recommendations in current guidelines. While the association between branch perfusion and aneurysm sac enlargement, as well as the efficacy of embolization for sac expansion, has been reported, a strong correlation with rupture or mortality has not been definitively established. Therefore, it is becoming increasingly important to evaluate the necessity and effectiveness of embolization or open surgical conversion as treatments for Type II endoleaks, and to clarify to what extent prophylactic embolization of branch vessels—either prior to or during EVAR—can reduce the need for secondary interventions.
|
| 3 |
Reappraisal of open surgical repair of abdominal aortic aneurysm in the endovascular era
In Japan, it has been 20 years since stent grafts for the treatment of abdominal aortic aneurysms (AAA) received regulatory approval. The package insert states that "when open surgery can be performed with relatively low risk, it should be considered the first-line treatment." However, stent grafts are now used in more than 50–60% of AAA cases. Initially, the lower perioperative mortality associated with EVAR was emphasized as a major advantage. However, as long-term outcomes have become clearer, the survival benefit has been refuted, and the high frequency of secondary interventions remains a notable disadvantage. Although device technology has improved, deployment techniques have advanced, and preventive measures for secondary interventions have been implemented, open surgical graft replacement still offers far superior curability. Furthermore, treatment outcomes in Japan have been more favorable compared to Western countries. Now that stent grafting has become a standard treatment for AAA, and under increasing pressure to reduce healthcare costs, it is necessary to re-evaluate the role of open surgical graft replacement.
|
| 4 |
Open treatment of infected abdominal aortic aneurysm
Endovascular aneurysm repair (EVAR) is increasingly performed for the treatment of abdominal aortic aneurysms (AAA). However, for infected AAA, the fundamental principle is to avoid leaving any foreign material behind, and therefore open surgery is generally selected. That said, in high-risk patients for open surgery, EVAR may be accepted as a bridge therapy to prevent imminent rupture. Recent registry data analyses have shown that outcomes with EVAR are not necessarily poor, and in selected cases, it may be considered a reasonable option. Nonetheless, open surgery remains the first-line treatment for infected AAA. The procedure itself is of the highest technical complexity, involving difficult tissue dissection, removal of infected tissue, securing adequate lower limb perfusion, and the challenging decision between in situ reconstruction or extra-anatomical bypass. Preoperative infection assessment and strategic planning are the true test of a vascular surgeon’s skill. This session will delve into the experiences and insights gained from these highly complex and often agonizing cases, with the aim of passing on this invaluable knowledge to the next generation.
|
| 5 |
Real world management of critical limb ischemia after Best-CLI trial
The BEST-CLI trial, a large-scale, prospective, randomized controlled study comparing surgical bypass and endovascular therapy for comprehensive treatment of chronic limb-threatening ischemia (CLTI), has attracted global attention. The trial demonstrated the superiority of autologous vein bypass when a suitable vein was available, significantly influencing treatment decision-making. However, in Japan, the situation is more complex due to a higher prevalence of dialysis-dependent and frail patients, as well as a greater frequency of below-the-knee and pedal artery disease and severe arterial calcification. These unique factors make it difficult to directly apply Western data to Japanese clinical practice. This symposium aims to examine how clinical strategies and practices have evolved following the BEST-CLI trial, and to discuss how its evidence should be interpreted and integrated into CLTI treatment in Japan. We hope to explore a path forward to bridge the gap between global evidence and local realities.
|
| 6 |
Management of vascular graft infection
Graft infection is one of the most serious complications in the field of cardiovascular surgery. Although its incidence is relatively low, once it occurs, it is associated with high mortality and amputation rates, significantly affecting patient prognosis and quality of life. Despite its severity, there remains a lack of clear clinical guidelines and robust evidence for its management. The diagnosis and treatment of graft infection involve numerous challenges at each step of care—including routes of infection, risk factors, the accuracy of imaging modalities, characteristics of causative microorganisms, selection of antibiotics, timing and approach of surgical intervention, and choice of reconstruction techniques. This session will focus on graft infections occurring below the abdominal aorta. By sharing experiences and insights from various institutions, we aim to deepen discussions and work toward establishing a comprehensive treatment strategy for tackling this formidable condition.
|
| 7 |
Early clinical results of aspiration system for acute limb ischemia
Treatment strategies for acute lower limb arterial occlusion are evolving from traditional surgical thrombectomy and bypass procedures to endovascular and hybrid approaches tailored to the specific pathology. In Western countries, the efficacy of catheter-directed thrombolysis (CDT) and thrombectomy has been well established, and non-surgical approaches are commonly adopted as standard treatments for Rutherford class IIa and IIb cases. In Japan, the prolonged suspension of urokinase supply made it difficult to continue CDT. However, thanks to the efforts of related academic societies, the thrombectomy device (INDIGO System) has now been approved for insurance coverage, paving the way for a new treatment paradigm. This symposium will explore the latest treatment strategies for acute lower limb arterial occlusion, share institutional initiatives, and discuss real-world challenges and future prospects. Through multifaceted discussion, we aim to contribute to the standardization and optimization of care in this critical clinical area.
|
| 8 |
Treatment of median arcuate ligament syndrome (MALS) associated visceral artery aneurysm
There is a hypothesis that stenosis or occlusion of the celiac artery (or superior mesenteric artery) due to median arcuate ligament syndrome (MALS) alters the hemodynamics of the so-called pancreatic arcade, resulting in aneurysm formation mainly in the visceral arteries, particularly the pancreaticoduodenal arteries. If one accepts the simple scenario that the occlusion causes changes in arcade blood flow leading to remodeling and subsequent vessel dilation, it would be desirable to perform ligament release in addition to aneurysm treatment. However, the ligament is located deeply and firmly in the operative field, and preventive surgery based on this hypothesis carries considerable risk. Treatment of celiac artery stenosis or occlusion due to MALS not only aims to restore blood flow but also has a procedural advantage as it facilitates access routes during embolization of the aneurysms. At present, whether it be ligament release, aneurysm resection or embolization, or bypass surgery accompanying these procedures, these treatments remain largely exploratory and lack solid evidence. We hope that by sharing the experiences and knowledge from various institutions, and by discussing these findings in the session, clearer treatment strategies will emerge.
|
■Congenital
| Session Theme | |
|---|---|
| 1 |
How Should We Approach Failing Fontan?: Current Status and Future Perspectives of Long-Term EC-TCPC Management
Fontan-type surgery has improved life expectancy and quality of life in single-ventricle patients, offering the prospect of stable long-term outcomes. However, in recent years, a range of mid- to long-term postoperative complications has been increasingly recognized, including progressive decline in cardiac output, veno-venous collaterals, arrhythmias, protein-losing enteropathy, and Fontan-associated liver disease (FALD). In patients with so-called “failed Fontan” physiology, the need for mechanical circulatory support or heart transplantation is expected to rise. While strategies such as conversion surgery and various management approaches have been implemented to prevent or ameliorate Fontan failure, comprehensive analyses of their current status remain insufficient.
This session will focus on surgical and hybrid strategies to mitigate “failing” Fontan physiology. Discussion topics will include the optimal size of the IVC–PA conduit, timing and techniques of atrioventricular valve interventions, arrhythmia management, the role of fenestration, and hemodynamic analyses, all from a long-term perspective. |
| 2 |
When Stents Complicate Surgery: Are We Ready for the Recovery Shot?
In recent years, the indications for stent placement in pediatric cardiology—including ductal and pulmonary vein stents—have been expanding. As a result, surgeons increasingly encounter the need for planned or unplanned operations following stent therapy. Surgical challenges in these cases include the need for vascular reconstruction due to stent migration or occlusion, as well as the risk of vascular injury during stent removal. Such situations often require tailored surgical techniques adapted to the specific characteristics of each case. This session aims to share experiences with surgical interventions following stent placement, fostering discussion on operative strategies and technical considerations. Additionally, it seeks to provide feedback to pediatric cardiologists regarding the indications and methods of stent therapy, with the ultimate goal of improving interdisciplinary planning and patient outcomes.
|
| 3 |
Should We Repair or Wait?: Strategic Management of Ductal-Dependent Pulmonary Circulation in the Neonatal Period
Ductus-dependent congenital heart diseases require intervention during the neonatal period, but the range of management options has expanded significantly. Beyond early primary surgical repair in the neonatal period, strategies now include deferring surgery until infancy with prostaglandin E1 infusion to maintain ductal patency while avoiding the risks of neonatal cardiopulmonary bypass, or using ductal stenting to achieve more reliable long-term patency. For ductus-dependent systemic circulation, such as in hypoplastic left heart syndrome (HLHS), bilateral pulmonary artery banding and ductal stenting have contributed to improved early survival. In conditions like d-TGA with intact ventricular septum (IVS), primary neonatal repair has achieved excellent outcomes. In contrast, for ductus-dependent pulmonary circulation amenable to biventricular repair—such as TOF with pulmonary atresia/stenosis (PA/PS) —there is now a pressing need to reexamine optimal timing of surgical intervention, bridging strategies, the choice between single-stage or staged repair, and the design of staged approaches. This session will invite discussion on these critical considerations to help define optimal management strategies for these complex patient groups.
|
| 4 |
AV Valve Repair in Single Ventricle Patients: Timing, Technique, (and Real-World Challenges)
Surgical management of atrioventricular (AV) valve disease in single-ventricle patients has long been the subject of extensive discussion. While delaying surgical intervention until the second stage of palliation has been associated with relatively favorable outcomes, significant challenges remain for patients with moderate or severe common AV valve regurgitation or tricuspid regurgitation present from the neonatal period. Key considerations—such as determining the optimal timing for surgery, accurately assessing valve morphology and severity, managing pulmonary blood flow, and selecting and combining surgical techniques—vary greatly depending on institutional strategies and experience. To achieve a successful Fontan circulation in the long term, a staged approach that also accounts for the potential need for future prosthetic valve replacement must be considered. This session aims to share institutional experiences, strategies, and technical innovations, with the goal of further improving outcomes in this complex patient population.
|
| 5 |
Do We Think Differently After Seeing the Model?: A Practical Assessment of 3D Cardiac Simulations
Patient-specific 3D-printed cardiac models generated from CT or MRI data are increasingly used both in Japan and internationally to support preoperative planning and provide hands-on simulation of surgical design and anastomotic techniques. Additionally, on-screen 3D CT visualizations, including glasses-free stereoscopic displays, have demonstrated growing utility in clinical practice. This session aims to go beyond discussing the value of these tools as merely “easy to understand” visual aids. Instead, it will focus on how 3D simulations have actually contributed—or could contribute—to concrete clinical decision-making, such as surgical approach selection or technique planning. By sharing real-world clinical cases, we hope to facilitate a discussion on the true clinical utility of 3D cardiac simulations in improving patient outcomes.
|
| 6 |
Is TPVI Always the Right First Step?: Balancing Early Intervention with Surgical PVR in Lifetime Planning
With the introduction and growing availability of transcatheter pulmonary valve implantation (TPVI) in Japan, the number of procedures performed has been rapidly increasing. Unlike transcatheter aortic valve implantation (TAVI), TPVI is primarily indicated in younger patients, who will likely require multiple reinterventions over their lifetime. Despite this, clear criteria for selecting between surgical pulmonary valve replacement (PVR) and TPVI, as well as optimal timing for intervention, remain undefined and vary significantly between institutions. This session aims to facilitate a comprehensive discussion on lifetime management of the pulmonary valve. We will examine data on surgical PVR outcomes and long-term prognosis, institutional practices regarding the choice between PVR and TPVI, and innovations aimed at reducing the invasiveness of surgical PVR. By sharing these diverse perspectives, we hope to deepen the discussion on how best to determine “when” and “which” intervention to choose in the context of lifelong patient care.
|
General Session (Oral/Poster/Video)
| A. Heart | |||
|---|---|---|---|
| A-01 | Congenital | A-01-01 | Congenital Heart Disease |
| A-01-02 | Adult Congenital | ||
| A-01-03 | Other | ||
| A-02 | Ischemic | A-02-01 | Coronary Artery Bypass |
| A-02-02 | Myocardial Infarction Complications | ||
| A-02-03 | Ischemic Cardiomyopathy | ||
| A-02-04 | Other | ||
| A-03 | Valvular Disease | A-03-01 | Aortic Valve |
| A-03-02 | TAVI | ||
| A-03-03 | Mitral Valve | ||
| A-03-04 | Mitral Valve (Functional MR) | ||
| A-03-05 | Tricuspid Valve | ||
| A-03-06 | Combined Valvular Disease | ||
| A-03-07 | MICS | ||
| A-03-08 | Other | ||
| A-04 | Endocarditis | ||
| A-05 | Arrhythmia | ||
| A-06 | Heart Failure・VAD・Heart Transplantation | ||
| A-07 | Other Heart Diseases | ||
| A-08 | Extracorporeal Circulation・Assist Circulation | ||
| A-09 | Intraoperative and Postoperative Management | ||
| A-10 | Postoperative Complications | ||
| A-11 | Examination・Diagnosis | ||
| A-12 | Basic Research | ||
| A-13 | Other | ||
| B. Vessels | |||
|---|---|---|---|
| B-01 | Aortic Dissection | B-01-01 | Type A Dissection |
| B-01-02 | Type B Dissection | ||
| B-01-03 | Chronic Dissection | ||
| B-01-04 | Dissection Complications | ||
| B-01-05 | Other | ||
| B-02 | Thoracic Aorta | B-02-01 | Aortic Root |
| B-02-02 | Ascending Arch | ||
| B-02-03 | Descending | ||
| B-02-04 | Extensive Aneurysm | ||
| B-02-05 | Other | ||
| B-03 | Thoracoabdominal Aorta | ||
| B-04 | Abdominal Aorta | ||
| B-05 | Peripheral Artery | ||
| B-06 | Vein | ||
| B-07 | Pulmonary Artery | ||
| B-08 | Stent Graft | B-08-01 | Thoracic |
| B-08-02 | Thoracoabdominal | ||
| B-08-03 | Abdominal | ||
| B-08-04 | Aortic Dissection | ||
| B-08-05 | Peripheral Artery | ||
| B-08-06 | Other | ||
| B-09 | Perioperative Management | ||
| B-10 | Examination・Diagnosis | ||
| B-11 | Basic Research | ||
| B-12 | Other | ||
| C. Regenerative Medicine | |||
|---|---|---|---|
| C-01 | Latest Technology | C-01-01 | Regenerative Medicine |
| C-01-02 | Latest Technology | ||
| C-01-03 | Other | ||
| D. Team Medical Care | |||
|---|---|---|---|
| D-01 | Training | D-01-01 | Education・Training |
| D-01-02 | Team Medical Care | ||
| D-01-03 | Other | ||
| E. Other | |
|---|---|
| E-01 | Other |
[Other Notes]
- Due to program scheduling requirements, we may request a different presentation format than what you registered. Please understand this in advance.
- If main theme sessions are not accepted, please also select whether you wish to present as a video presentation or general presentation.
- When applying for either type of presentation, acceptance will be determined again in the same manner as general presentations.
- After selecting a general abstract, please choose whether or not you would like to accept a presentation in the thematic session. If your abstract is judged to be excellent as a result of peer review, you may be asked to present it in the thematic session.
- Please note that the presentation categories for general presentations and video presentations may be changed from your registered category depending on content and available presentation slots.
Character Limit
- English presentation title：No limit
- Maximum number of registrable authors (lead author + co-authors)： Up to 21
- Maximum number of registrable affiliated institutions：Up to 10
Presentation Language
| Main Theme Session | General Presentations | |
|---|---|---|
| Abstract Language | English | Japanese or English (either acceptable) |
| Slide Language | ||
| Presentation Language |
Application Method
For applications to this conference, please submit slide-format abstract PDFs rather than text-based abstracts.
Important Notes for Slide Creation
- Please create slide-format abstracts using the template and compile them into exactly 7 slides. You may use photographs, figures, and tables.
- Please convert to PDF and upload to the presentation registration system. Do not embed videos.
- Please do not include your affiliation or name in the slide-format abstract, as this information will be entered into the presentation registration system.
- You may use different text colors and styles (bold, etc.) for better readability, but please ensure the main text font size is at least 28 points (excluding text within figures and tables).
- Figures and tables may be inserted. The number of figures and tables is not restricted to the template layout frames.
- Please create slides in 16:9 format.
- The maximum file size for uploaded PDF data is 10MB. Please ensure your file is within this limit.
-
Please structure the 7 slides with the following content:
・Slide 1: Title
・Slide 2: Background and Objective
・Slide 3: Subjects
・Slide 4: Methods
・Slide 5: Results 1
・Slide 6: Results 2
・Slide 7: Conclusion -
If you are using macOS, an upload error may occur if your filename contains the following half-width characters. In such cases, please remove these characters from the filename.
¥ ⁄ : * ? " > < |
Please download the template from the button below.
PDF Conversion Method
- For PowerPoint：
File > Export > Create PDF/XPS: Select the "Minimum size (online publishing) (M)" radio button > Publish
- For Keynote：
File > Export > Select PDF > Next > Enter filename and select destination folder > Export
Presentation Registration Method
Registration is only available online through the presentation registration system. Please register using the "New Presentation Registration" button at the bottom of this page.
Presentation Registration and Password
A registration number and password will be issued upon presentation registration. During the presentation registration period, you can check, modify, and delete your presentation using the registration number and password, so please manage them carefully and do not forget them. To maintain security, we cannot respond to any inquiries regarding passwords.
Presentation Receipt and Acceptance Notification
1. Presentation Receipt Confirmation
When you register, modify, or delete a presentation, an automatic email will be sent to the email address you entered during application. Please be sure to check this automatic email. This email serves as your receipt notification. If you do not receive the receipt notification email within one day after registration, it may have been filtered into your spam folder or registration may not have been completed. If it is not in your spam folder, please check from the "Confirmation/Modification Screen" to ensure your registered email address is correct. If your email address is correct, please contact the management office before the presentation application deadline.
Management Office E-mail: jscvs2026-abs@congre.co.jp
2. Presentation Acceptance and Presentation Schedule
Notification of presentation acceptance will be sent to the email address entered during presentation registration in early December.
Presentation Registration
Inquiries Regarding Presentation Registration Methods
56th Annual Scientific Meeting of the Japanese Association for Thoracic
Surgery Management Office Congre Inc.
TEL：03-3510-3701 FAX：03-3510-3702
E-mail：jscvs2026-abs@congre.co.jp
